Embracing big data and emerging technologies in drug safety

Which new approaches are pharma companies taking to exploit opportunities offered by big data? We’ll be answering this question and many more as we discuss big data and related innovative technologies at World Drug Safety Congress Europe. Hear from a plethora of thought leaders who will be sharing real life examples of how to develop big data programmes and social media …

Download: Lifecycle safety data analysis and signal management

At last year’s World Drug Safety Congress Europe, Dr Ulrich Vogel, Head Strategic Data Analysis, Global Pharmacovigilance, Boehringer Ingelheim gave a presentation entitled “Lifecycle safety data analysis and signal management” Download the presentation and learn: Technical expectation to signal management Conceptual expectation to signal management Real world representation Pharmacovigilance data monitoring Challenges in signal interpretation Case study – Abstraction / Representation Framing …

Could automation be the answer to optimal cell line identification?

What role can automation play in the identification of the best cell line? This question was addressed by Anne Tolstrup, Head of Cell Culture II at Boehringer Ingelheim, at the 2012 Cell Culture World Congress.  During her presentation Anne posed the following questions- "what are the limiting factors of existing early predictive tools?" and "could the use of automated platforms …

Top 3 partnerships between Big Pharma and Academia

As the drug discovery business goes through difficult times, drug candidates can't seem to move through the pharmaceutical industry process fast enough. As well, entrepreneurs are struggling to get the funding they need to carry through their ideas to fruition.  Can partnerships between big pharma and academia help?  With the many recent cases of new alliances and partnerships in the …